Intellia Therapeutics - Revolutionize the course of medicine
Jan 6, 2025 · Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies.
Our Pipeline - Intellia Therapeutics
Jan 9, 2025 · Intellia is building a pipeline of in vivo and ex vivo therapies, as well as continuing to develop innovative modular platform capabilities.
Intellia Therapeutics - investor relations
Jan 6, 2025 · The Investor Relations website contains information about Intellia Therapeutics's business for stockholders, potential investors, and financial analysts.
About - Intellia Therapeutics
Learn more about Intellia, a clinical-stage genome editing company, developing novel, potentially curative therapeutics using CRISPR.
Press Releases - Intellia Therapeutics
Jan 6, 2025 · Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
Careers - Intellia Therapeutics
At Intellia, we are revolutionizing medicine by harnessing the power of genome editing to develop CRISPR one-time treatments. We bring new hope for people living with conditions, including cancer, genetic disorders, viral infections, inflammatory disorders and many more.
Clinical Trials - Intellia Therapeutics
Intellia is committed to developing gene editing treatments for those living with severe and life-threatening genetic diseases. We are currently investigating our CRISPR-based technology in clinical trials as single-dose treatments.
Full-Spectrum Approach - Intellia Therapeutics
Intellia is engineering T cells against specific cancer antigens. therapies to provide them with particular enhanced attributes that may more effectively treat oncological and autoimmune diseases.
Our Science - Intellia Therapeutics
Today, scientists at Intellia are developing this technology to make targeted changes to genes directly implicated in human disease. In the future, Intellia hopes to use its CRISPR technology to address a variety of severe, life-threatening diseases.
Scientific Publications & Presentations - Intellia Therapeutics
Find the latest Scientific Publications & Presentations from Intellia, a clinical-stage genome editing company.